Literature DB >> 1535057

Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats.

N Perico1, A Benigni, M Gabanelli, A Piccinelli, M Ròg, C De Riva, G Remuzzi.   

Abstract

The relative contribution of atrial natriuretic peptide (ANP) and vasodilatory prostaglandins to hyperfiltration in Wistar rats with experimental diabetes was studied 6-8 wk after streptozocin injection. Plasma levels of immunoreactive ANP were significantly higher (P less than 0.01) in hyperglycemic diabetic (72.9 +/- 11.7 pg/ml) than in normoglycemic diabetic (44.8 +/- 8.6 pg/ml) or nondiabetic (40.0 +/- 6.8 pg/ml) rats. Blocking endogenous ANP by specific ANP-antiserum infusion reduced significantly (P less than 0.01) glomerular filtration rate (GFR) and renal plasma flow (RPF) of hyperglycemic rats compared with preinfusion values (1.23 +/- 0.06-1.02 +/- 0.04; 2.87 +/- 0.25-2.40 +/- 0.10 ml.min-1.100 g-1, respectively). However, correction of hyperfiltration and hyperperfusion was only partial (nondiabetic rats GFR 0.85 +/- 0.07; RPF 2.27 +/- 0.13 ml.min-1.100 g-1). Because diabetic rats with hyperglycemia also had an increased urinary excretion of prostacyclin metabolite 6-keto-prostaglandin F1 alpha (220.6 +/- 62.8 ng/24 h) compared with nondiabetic rats (51.2 +/- 2.7 ng/24 h), we wondered whether excessive prostacyclin formation contributed to hyperfiltration and hyperperfusion in this setting. Indomethacin infusion partially reduced GFR (1.25 +/- 0.07 to 1.06 +/- 0.07 ml.min-1.100 g-1, P less than 0.05) and RPF (2.85 +/- 0.11 to 2.46 +/- 0.12 ml.min-1.100 g-1, P less than 0.01) in diabetic rats. The combined infusion of ANP antiserum and indomethacin normalized GFR and RPF in diabetic rats with hyperglycemia (1.27 +/- 0.05 to 0.88 +/- 0.05 and 2.84 +/- 0.10 to 2.22 +/- 0.06 ml.min-1.100 g-1, respectively; P less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1535057     DOI: 10.2337/diab.41.4.533

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

1.  Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes.

Authors:  R Komers; J N Lindsley; T T Oyama; W E Schutzer; J F Reed; S L Mader; S Anderson
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 2.  Update on Pathogenesis of Glomerular Hyperfiltration in Early Diabetic Kidney Disease.

Authors:  Yang Yang; Gaosi Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-19       Impact factor: 6.055

3.  Atrial natriuretic peptide increases urinary albumin excretion in people with normoalbuminuric type-2 diabetes.

Authors:  K B Moore; K McKenna; M Osman; W P Tormey; D McDonald; C J Thompson
Journal:  Ir J Med Sci       Date:  2007-05-03       Impact factor: 1.568

4.  Urinary kallikrein excretion in type 1 (insulin-dependent) diabetes mellitus.

Authors:  A Manto; P Cotroneo; G Porcelli; G D'Errico; G Marra; P Magnani; P Tilli; A V Greco; G Ghirlanda
Journal:  Diabetologia       Date:  1993-05       Impact factor: 10.122

Review 5.  Pathophysiology of the diabetic kidney.

Authors:  Volker Vallon; Radko Komers
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

6.  Prevention of glomerular hyperfiltration in rats with streptozotocin-induced diabetes by an atrial natriuretic peptide receptor antagonist.

Authors:  K Sakamoto; R Kikkawa; M Haneda; Y Shigeta
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122

7.  Inhibition of Prostaglandin Transporter (PGT) Promotes Perfusion and Vascularization and Accelerates Wound Healing in Non-Diabetic and Diabetic Rats.

Authors:  Zhongbo Liu; Outhiriaradjou Benard; Mahrukh M Syeda; Victor L Schuster; Yuling Chi
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.